Treatment group | Â | Days post-treatmenta | Â | ||||
---|---|---|---|---|---|---|---|
Day 0 | Day 7 | Day 14 | Day 28–30 | Day 42–45 | Day 56–60 | ||
Sarolanerb | # Dogs | 28 | 28 | 28 | 28 | 28 | 27 |
Mean PVAS Scored | 7.30 | 2.76 | 2.43 | 2.25 | 1.25 | 0.83 | |
SD | 2.22 | 2.67 | 2.39 | 2.23 | 1.73 | 1.15 | |
Range | 1.3–10.0 | 0–9.8 | 0.2–9.5 | 0–6.5 | 0–7.8 | 0–4.1 | |
Reduction (%)e | Â | 62.23 | 66.68 | 69.18 | 82.88 | 88.64 | |
# (%) ≤ 1.9 | 2 (7.14%) | 13 (46.43%) | 16 (57.14%) | 13 (46.43%) | 21 (75.0%) | 23 (85.19%) | |
Spinosadc | # Dogs | 25 | 25 | 24 | 25 | 25 | 23 |
Mean PVAS Scored | 7.43 | 3.23 | 2.69 | 2.85 | 1.58 | 1.07 | |
SD | 1.61 | 2.21 | 2.50 | 2.40 | 1.79 | 1.75 | |
Range | 3.7–10.0 | 0.1–7.6 | 0–9.5 | 0–8.8 | 0–7.8 | 0–7.3 | |
Reduction (%)e | Â | 56.54 | 63.76 | 61.66 | 78.73 | 85.60 | |
# (%) ≤ 1.9 | 0 (0.0%) | 8 (32.00%) | 13 (54.17%) | 11 (44.00%) | 21 (84.0%) | 20 (85.60%) |